Exicure, Inc. (XCUR) stock
XCURNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.08+0.01 (+0.93%)
Close on Nov 17, 2026Market cap $7.07MP/E –Yield –
Exicure r&d expenses
Research and development expenses are spending on new products and technology.
Exicure's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.03M, up 16.4% year over year. For fiscal 2025 it was $3.29M. The highest annual figure on record is $48.98M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.29M | – |
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $1.42M | -92.8% |
| FY2022 | Dec 31, 2022 | $19.77M | -59.6% |
| FY2021 | Dec 31, 2021 | $48.98M | +52.6% |
| FY2020 | Dec 31, 2020 | $32.09M | +65.9% |
| FY2019 | Dec 31, 2019 | $19.34M | +37.0% |
| FY2018 | Dec 31, 2018 | $14.12M | +7.9% |
| FY2017 | Dec 31, 2017 | $13.08M | -4.2% |
| FY2016 | Dec 31, 2016 | $13.66M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $174.00K | -81.4% |
| Q1 FY2026 | Mar 31, 2026 | $312.00K | -61.4% |
| Q4 FY2025 | Dec 31, 2025 | $655.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $888.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $935.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $808.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.42M | -80.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.07M | -90.6% |
| Q3 FY2022 | Sep 30, 2022 | $4.81M | -70.8% |
| Q2 FY2022 | Jun 30, 2022 | $6.75M | -37.8% |
| Q1 FY2022 | Mar 31, 2022 | $7.14M | -30.4% |
| Q4 FY2021 | Dec 31, 2021 | $11.42M | +15.7% |
| Q3 FY2021 | Sep 30, 2021 | $16.46M | +80.1% |
| Q2 FY2021 | Jun 30, 2021 | $10.84M | +54.7% |
| Q1 FY2021 | Mar 31, 2021 | $10.26M | +68.9% |
| Q4 FY2020 | Dec 31, 2020 | $9.87M | +19.4% |
| Q3 FY2020 | Sep 30, 2020 | $9.14M | +115.3% |
| Q2 FY2020 | Jun 30, 2020 | $7.01M | +104.1% |
| Q1 FY2020 | Mar 31, 2020 | $6.08M | +78.9% |
| Q4 FY2019 | Dec 31, 2019 | $8.27M | +174.8% |
| Q3 FY2019 | Sep 30, 2019 | $4.25M | +6.1% |
| Q2 FY2019 | Jun 30, 2019 | $3.43M | -10.5% |
| Q1 FY2019 | Mar 31, 2019 | $3.40M | +3.7% |
| Q4 FY2018 | Dec 31, 2018 | $3.01M | -5.1% |
| Q3 FY2018 | Sep 30, 2018 | $4.00M | -24.9% |
| Q2 FY2018 | Jun 30, 2018 | $3.84M | +58.9% |
| Q1 FY2018 | Mar 31, 2018 | $3.28M | – |
| Q4 FY2017 | Dec 31, 2017 | $3.17M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.33M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.41M | – |
See a number that looks wrong?